ICD-10-PCS XW0 New Technology: Anatomical Regions Introduction

The ICD-10-PCS root operation Introduction (code XW0) in the New Technology section refers to the insertion of a therapeutic substance or technology into an anatomical region. This operation involves delivering innovative treatments or agents into the body for diagnostic, therapeutic, or prophylactic purposes.

Examples of the Introduction operation include the administration of various new technologies such as monoclonal antibodies, antineoplastics, vaccines, or engineered tissues. For instance, the introduction of Daratumumab and Hyaluronidase-fihj into subcutaneous tissue via a percutaneous approach is coded as XW01318. Similarly, introducing a COVID-19 vaccine into muscle through a percutaneous approach is represented by codes like XW023U6. Other examples include the introduction of paclitaxel-coated balloon technology into the coronary artery using a percutaneous approach, demonstrating the diverse therapeutic applications covered by this root operation.

Accurate use of these codes supports comprehensive documentation of advanced medical treatments involving new technological substances and delivery methods within the ICD-10-PCS system.

List of ICD-10-PCS codes used to specify XW0 - Introduction (putting in or on a therapeutic, diagnostic, nutritional, physiological or prophylactic substance except blood or blood products). There are a total of 182 procedure codes in this section.

• XW0 - New Technology, Anatomical Regions, Introduction

• XW00X27 - Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7

• XW01318 - Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group...

• XW01329 - Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

• XW01348 - Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

• XW0136A - Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10

• XW01397 - Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

• XW013F5 - Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technolo...

• XW013G6 - Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

• XW013H6 - Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology...

• XW013K6 - Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

• XW013L9 - Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

• XW013S6 - Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

• XW013S9 - Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

• XW013T6 - Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

• XW013U6 - Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

• XW013V7 - Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

• XW013W5 - Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

• XW013W7 - Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

• XW01X27 - Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

• XW020D8 - Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8

• XW023S6 - Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6

• XW023T6 - Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6

• XW023U6 - Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

• XW023V7 - Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7

• XW023W7 - Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7

• XW023X7 - Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group ...

• XW023Y7 - Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

• XW03306 - Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW03308 - Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8

• XW03326 - Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW0333A - Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group...

• XW03336 - Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW0334A - Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group ...

• XW0335A - Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group ...

• XW03358 - Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8

• XW03357 - Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW03368 - Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group...

• XW03366 - Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW03367 - Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW03372 - Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2

• XW03378 - Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

• XW03377 - Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW03387 - Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW0338A - Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

• XW03388 - Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8

• XW03396 - Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group ...

• XW03398 - Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8

• XW0339A - Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

• XW033A6 - Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033A7 - Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW033B7 - Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW033B3 - Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Tec...

• XW033B6 - Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033BA - Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group...

• XW033C6 - Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033C7 - Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous ...

• XW033CA - Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

• XW033D6 - Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033DA - Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Appro...

• XW033E6 - Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033E5 - Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5

• XW033F6 - Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033FA - Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous App...

• XW033F3 - Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology G...

• XW033F5 - Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology G...

• XW033G7 - Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous ...

• XW033G6 - Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033G5 - Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

• XW033H7 - Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group ...

• XW033H6 - Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Gro...

• XW033H5 - Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

• XW033J7 - Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW033K7 - Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW033K9 - Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9

• XW033L6 - Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

• XW033L7 - Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

• XW033M7 - Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Grou...

• XW033N7 - Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group...

• XW033P9 - Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9

• XW033Q9 - Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9

• XW033Q5 - Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

• XW033R9 - Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9

• XW033S5 - Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

• XW033W5 - Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

• XW04306 - Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6

• XW04308 - Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8

• XW04326 - Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6

• XW0433A - Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

• XW04336 - Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

• XW0434A - Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

• XW0435A - Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

• XW04358 - Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

• XW04357 - Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

• XW04368 - Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

• XW04366 - Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

• XW04367 - Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7

• XW04372 - Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

• XW04378 - Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

• XW04377 - Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7

• XW04387 - Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7

• XW0438A - Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

• XW04388 - Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8

• XW04396 - Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

• XW04398 - Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8

• XW0439A - Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

• XW043A6 - Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043A7 - Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043B7 - Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043B3 - Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Techno...

• XW043B6 - Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043BA - Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

• XW043C6 - Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043C7 - Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous App...

• XW043CA - Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

• XW043D6 - Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043E6 - Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043E5 - Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

• XW043F6 - Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043FA - Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approa...

• XW043F3 - Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Grou...

• XW043F5 - Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Grou...

• XW043G7 - Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous App...

• XW043G6 - Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043G5 - Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5

• XW043H7 - Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043H6 - Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group ...

• XW043H5 - Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5

• XW043J7 - Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043K7 - Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043K9 - Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9

• XW043L6 - Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6

• XW043L7 - Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043M7 - Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043N7 - Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

• XW043P9 - Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9

• XW043Q9 - Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9

• XW043Q5 - Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

• XW043R9 - Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9

• XW043S5 - Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

• XW043W5 - Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

• XW053T9 - Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Gro...

• XW0DX38 - Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8

• XW0DX66 - Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6

• XW0DX82 - Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2

• XW0DXF5 - Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Gro...

• XW0DXJ9 - Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9

• XW0DXK8 - Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8

• XW0DXM6 - Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6

• XW0DXN9 - Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9

• XW0DXR7 - Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7

• XW0G738 - Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

• XW0G7K8 - Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

• XW0G7M6 - Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6

• XW0G7R7 - Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7

• XW0G886 - Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New ...

• XW0H738 - Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

• XW0H7K8 - Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

• XW0H7M6 - Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6

• XW0H7R7 - Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7

• XW0H7X8 - Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificia...

• XW0H886 - Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New ...

• XW0J3HA - Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approac...

• XW0J3JA - Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approa...

• XW0J3KA - Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Appr...

• XW0J3LA - Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneo...

• XW0K3HA - Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Appro...

• XW0K3JA - Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Appr...

• XW0K3KA - Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Ap...

• XW0K3LA - Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutan...

• XW0L3HA - Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous App...

• XW0L3JA - Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Ap...

• XW0L3KA - Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous ...

• XW0L3LA - Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percut...

• XW0M3HA - Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutane...

• XW0M3JA - Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutan...

• XW0M3KA - Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percut...

• XW0M3LA - Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries,...

• XW0Q316 - Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6

• XW0U0GA - Introduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into ...

• XW0V0P7 - Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7

• XW0V3WA - Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10